1Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Division of Gastrointestinal Surgery, Department of Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Copyright © 2018 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Group 1a) (n=147) | Group 2b) (n=260) | Group 3c) (n=62) | p-value | |
---|---|---|---|---|
Age (mean±SD) | 62.6±10.6 | 60.2±11.5 | 61.2±10.4 | 0.149 |
Sex, Male | 107 (72.8%) | 162 (62.3%) | 36 (58.1%) | 0.048 |
BMI, kg/m2 (mean±SD) | 23.9±2.8 | 22.9±3.3 | 21.5±2.8 | <0.001 |
History of first degree relatives with stomach cancer | 35 (23.8%) | 64 (24.6%) | 10 (16.1%) | 0.357 |
History of previous malignancy | 17 (11.6%) | 25 (9.6%) | 6 (9.7%) | 0.127 |
None | 130 (88.4%) | 235 (90.4%) | 56 (90.3%) | |
Colorectal | 8 (5.4%) | 3 (1.2%) | 1 (1.6%) | |
Esophagus | 3 (2.0%) | 1 (0.4%) | 0 (0.0%) | |
Lung | 1 (0.7%) | 1 (0.4%) | 0 (0.0%) | |
Liver | 1 (0.7%) | 2 (0.8%) | 1 (1.6%) | |
Breast | 1 (0.7%) | 2 (0.8%) | 2 (3.2%) | |
Others | 3 (2.0%) | 16 (6.2%) | 2 (3.2%) | |
H. pylori infection status | 88/141 (62.4%) | 109/162 (67.3%) | 22/30 (73.3%) | 0.442 |
Experience of regular gastric cancer surveillance (2-yr interval) | 101 (70.6%) | 128 (49.6%) | 17 (27.4%) | <0.001 |
Unknownd) | 4 | 2 | 0 | |
Differentiated stomach cancer | 139 (94.6%) | 124 (47.7%) | 17 (27.4%) | <0.001 |
Stage | <0.001 | |||
I | 147 (100%) | 194 (74.6%) | 0 (0 %) | |
II | 0 (0%) | 28 (10.8%) | 3 (4.8%) | |
III | 0 (0%) | 38 (14.6%) | 4 (6.5%) | |
IV | 0 (0%) | 0 (0%) | 55 (88.7%) |
SD, standard deviation; BMI, body mass index; H. pylori, Helicobacter pylori.
a)Patients undergoing endoscopic resection and pathologically confirmed curative resection.
b)Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection.
c)Patients with distant metastasis or pathologically non-curative resection after surgical treatment.
d)Patients who could not remember the cancer surveillance interval were not included (n=6).
Group 1a) (n=147) | Group 2b) (n=260) | Group 3c) (n=62) | p-value | |
---|---|---|---|---|
Foreign body sensation | 17 (12.0%) | 31 (12.3%) | 10 (16.4%) | 0.653 |
Dysphagia | 11 (7.8%) | 13 (5.2%) | 8 (13.1%) | 0.085 |
Odynophagia | 2 (1.4%) | 7 (2.8%) | 5 (8.3%) | 0.032 |
Postprandial satiety | 43 (30.7%) | 93 (36.9%) | 34 (55.7%) | 0.003 |
Early satiety | 17 (12.1%) | 59 (23.4%) | 33 (53.2%) | <0.001 |
Heartburn | 38 (27.0%) | 78 (30.8%) | 21 (34.4%) | 0.530 |
Epigastric pain | 21 (14.9%) | 59 (23.4%) | 20 (32.8%) | 0.014 |
Nausea | 21 (14.9%) | 39 (15.5%) | 21 (33.9%) | 0.002 |
Vomiting | 7 (5.0%) | 25 (10.0%) | 15 (24.6%) | <0.001 |
Anorexia | 13 (9.2%) | 53 (21.1%) | 32 (51.6%) | <0.001 |
Dizziness | 43 (30.5%) | 72 (28.2%) | 20 (32.3%) | 0.783 |
Melena | 13 (9.2%) | 33 (13.0%) | 16 (25.8%) | 0.006 |
Hematochezia | 2 (1.4%) | 6 (2.4%) | 2 (3.3%) | 0.681 |
Hematemesis | 0 (0.0%) | 5 (2.0%) | 5 (8.2%) | 0.001 |
Clinically important weight lossd) | 18 (12.2%) | 58 (22.3%) | 36 (58.1%) | <0.001 |
Initial Hb <10 g/dL | 3 (2.0%) | 18 (6.9%) | 20 (32.3%) | <0.001 |
Hb, hemoglobin.
a)Patients undergoing endoscopic resection and pathologically confirmed curative resection.
b)Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection.
c)Patients with distant metastasis or pathologically non-curative resection after surgical treatment.
d)Unintentional weight loss of more than 5% of usual body weight over 12 months.
Factors |
Univariate analysis |
Multivariate analysis |
||
---|---|---|---|---|
Odds ratio (95% CI) | p-value | odds ratio (95% CI) | p-value | |
Age <60 | 1.141 (0.768–1.693) | 0.514 | 1.506 (0.673–3.369) | 0.319 |
Male | 1.675 (1.093–2.568) | 0.018 | 1.054 (0.479–2.321) | 0.896 |
Hb >10 g/dL | 6.423 (1.949–21.162) | 0.002 | 3.447 (0.736–16.147) | 0.116 |
Absence of first degree relative with stomach cancer | 0.955 (0.603–1.512) | 0.844 | 1.219 (0.509–2.918) | 0.656 |
Absence of clinically important weight lossa) | 2.611 (1.293–5.275) | 0.007 | 1.488 (0.671–3.300) | 0.328 |
Regular gastric cancer surveillanceb) (within 2 yr) | 2.902 (1.903–4.425) | <0.001 | 6.099 (2.532–14.933) | <0.001 |
Group 1a) (n=147) | Group 2b) (n=260) | Group 3c) (n=62) | p-value | |
---|---|---|---|---|
Experience participating in KNCSP | 90 (61.2%) | 156 (60.0%) | 26 (41.9%) | 0.022 |
Experience with endoscopy or gastrography before diagnosis | 133 (93.0%) | 183 (70.9%) | 32 (51.6%) | <0.001 |
Reason for examination | <0.001 | |||
Regular check up | 130 (88.4%) | 200 (76.9%) | 25 (40.3%) | |
Symptom | 17 (11.6%) | 60 (23.1%) | 37 (59.7%) | |
Surveillance method | 0.134 | |||
Endoscopy | 118 (88.7%) | 147 (80.3%) | 27 (84.4%) | |
Radiology | 15 (11.3%) | 36 (19.7%) | 5 (15.6%) | |
Surveillance intervald) | <0.001 | |||
1 yr | 54 (37.8%) | 61 (23.6%) | 11 (17.7%) | |
2 yr | 47 (32.9%) | 67 (26.0%) | 6 (9.7%) | |
Over 2 yr | 32 (22.4%) | 55 (21.3%) | 15 (24.2%) | |
None | 10 (7.0%) | 75 (29.1%) | 30 (48.4%) |
KNCSP, Korean National Cancer Screening Program.
a)Patients undergoing endoscopic resection and pathologically confirmed curative resection.
b)Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection.
c)Patients with distant metastasis or pathologically non-curative resection after surgical treatment.
d)Patients who did not know the cancer surveillance interval were not included (n=6).
Cancer surveillance interval | Adjusted odd ratio (95% CI) | p-value |
---|---|---|
1 yr | 49.969 (6.340–393.827) | <0.001 |
2 yr | 15.283 (1.833–127.406) | 0.012 |
Over 2 yr | 10.651 (1.248–90.871) | 0.031 |
None | 1 |
Group 1 |
Group 2 |
Group 3 |
p-value | |
---|---|---|---|---|
Age (mean±SD) | 62.6±10.6 | 60.2±11.5 | 61.2±10.4 | 0.149 |
Sex, Male | 107 (72.8%) | 162 (62.3%) | 36 (58.1%) | 0.048 |
BMI, kg/m2 (mean±SD) | 23.9±2.8 | 22.9±3.3 | 21.5±2.8 | <0.001 |
History of first degree relatives with stomach cancer | 35 (23.8%) | 64 (24.6%) | 10 (16.1%) | 0.357 |
History of previous malignancy | 17 (11.6%) | 25 (9.6%) | 6 (9.7%) | 0.127 |
None | 130 (88.4%) | 235 (90.4%) | 56 (90.3%) | |
Colorectal | 8 (5.4%) | 3 (1.2%) | 1 (1.6%) | |
Esophagus | 3 (2.0%) | 1 (0.4%) | 0 (0.0%) | |
Lung | 1 (0.7%) | 1 (0.4%) | 0 (0.0%) | |
Liver | 1 (0.7%) | 2 (0.8%) | 1 (1.6%) | |
Breast | 1 (0.7%) | 2 (0.8%) | 2 (3.2%) | |
Others | 3 (2.0%) | 16 (6.2%) | 2 (3.2%) | |
H. pylori infection status | 88/141 (62.4%) | 109/162 (67.3%) | 22/30 (73.3%) | 0.442 |
Experience of regular gastric cancer surveillance (2-yr interval) | 101 (70.6%) | 128 (49.6%) | 17 (27.4%) | <0.001 |
Unknown |
4 | 2 | 0 | |
Differentiated stomach cancer | 139 (94.6%) | 124 (47.7%) | 17 (27.4%) | <0.001 |
Stage | <0.001 | |||
I | 147 (100%) | 194 (74.6%) | 0 (0 %) | |
II | 0 (0%) | 28 (10.8%) | 3 (4.8%) | |
III | 0 (0%) | 38 (14.6%) | 4 (6.5%) | |
IV | 0 (0%) | 0 (0%) | 55 (88.7%) |
Group 1 |
Group 2 |
Group 3 |
p-value | |
---|---|---|---|---|
Foreign body sensation | 17 (12.0%) | 31 (12.3%) | 10 (16.4%) | 0.653 |
Dysphagia | 11 (7.8%) | 13 (5.2%) | 8 (13.1%) | 0.085 |
Odynophagia | 2 (1.4%) | 7 (2.8%) | 5 (8.3%) | 0.032 |
Postprandial satiety | 43 (30.7%) | 93 (36.9%) | 34 (55.7%) | 0.003 |
Early satiety | 17 (12.1%) | 59 (23.4%) | 33 (53.2%) | <0.001 |
Heartburn | 38 (27.0%) | 78 (30.8%) | 21 (34.4%) | 0.530 |
Epigastric pain | 21 (14.9%) | 59 (23.4%) | 20 (32.8%) | 0.014 |
Nausea | 21 (14.9%) | 39 (15.5%) | 21 (33.9%) | 0.002 |
Vomiting | 7 (5.0%) | 25 (10.0%) | 15 (24.6%) | <0.001 |
Anorexia | 13 (9.2%) | 53 (21.1%) | 32 (51.6%) | <0.001 |
Dizziness | 43 (30.5%) | 72 (28.2%) | 20 (32.3%) | 0.783 |
Melena | 13 (9.2%) | 33 (13.0%) | 16 (25.8%) | 0.006 |
Hematochezia | 2 (1.4%) | 6 (2.4%) | 2 (3.3%) | 0.681 |
Hematemesis | 0 (0.0%) | 5 (2.0%) | 5 (8.2%) | 0.001 |
Clinically important weight loss |
18 (12.2%) | 58 (22.3%) | 36 (58.1%) | <0.001 |
Initial Hb <10 g/dL | 3 (2.0%) | 18 (6.9%) | 20 (32.3%) | <0.001 |
Factors | Univariate analysis |
Multivariate analysis |
||
---|---|---|---|---|
Odds ratio (95% CI) | p-value | odds ratio (95% CI) | p-value | |
Age <60 | 1.141 (0.768–1.693) | 0.514 | 1.506 (0.673–3.369) | 0.319 |
Male | 1.675 (1.093–2.568) | 0.018 | 1.054 (0.479–2.321) | 0.896 |
Hb >10 g/dL | 6.423 (1.949–21.162) | 0.002 | 3.447 (0.736–16.147) | 0.116 |
Absence of first degree relative with stomach cancer | 0.955 (0.603–1.512) | 0.844 | 1.219 (0.509–2.918) | 0.656 |
Absence of clinically important weight loss |
2.611 (1.293–5.275) | 0.007 | 1.488 (0.671–3.300) | 0.328 |
Regular gastric cancer surveillance |
2.902 (1.903–4.425) | <0.001 | 6.099 (2.532–14.933) | <0.001 |
Group 1 |
Group 2 |
Group 3 |
p-value | |
---|---|---|---|---|
Experience participating in KNCSP | 90 (61.2%) | 156 (60.0%) | 26 (41.9%) | 0.022 |
Experience with endoscopy or gastrography before diagnosis | 133 (93.0%) | 183 (70.9%) | 32 (51.6%) | <0.001 |
Reason for examination | <0.001 | |||
Regular check up | 130 (88.4%) | 200 (76.9%) | 25 (40.3%) | |
Symptom | 17 (11.6%) | 60 (23.1%) | 37 (59.7%) | |
Surveillance method | 0.134 | |||
Endoscopy | 118 (88.7%) | 147 (80.3%) | 27 (84.4%) | |
Radiology | 15 (11.3%) | 36 (19.7%) | 5 (15.6%) | |
Surveillance interval |
<0.001 | |||
1 yr | 54 (37.8%) | 61 (23.6%) | 11 (17.7%) | |
2 yr | 47 (32.9%) | 67 (26.0%) | 6 (9.7%) | |
Over 2 yr | 32 (22.4%) | 55 (21.3%) | 15 (24.2%) | |
None | 10 (7.0%) | 75 (29.1%) | 30 (48.4%) |
Cancer surveillance interval | Adjusted odd ratio (95% CI) | p-value |
---|---|---|
1 yr | 49.969 (6.340–393.827) | <0.001 |
2 yr | 15.283 (1.833–127.406) | 0.012 |
Over 2 yr | 10.651 (1.248–90.871) | 0.031 |
None | 1 |
SD, standard deviation; BMI, body mass index; Patients undergoing endoscopic resection and pathologically confirmed curative resection. Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection. Patients with distant metastasis or pathologically non-curative resection after surgical treatment. Patients who could not remember the cancer surveillance interval were not included (
Hb, hemoglobin. Patients undergoing endoscopic resection and pathologically confirmed curative resection. Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection. Patients with distant metastasis or pathologically non-curative resection after surgical treatment. Unintentional weight loss of more than 5% of usual body weight over 12 months.
CI, confidence interval; Hb, hemoglobin. Unintentional weight loss of more than 5% of usual body weight over 12 months. Patients who could not remember the cancer surveillance interval were not included (
KNCSP, Korean National Cancer Screening Program. Patients undergoing endoscopic resection and pathologically confirmed curative resection. Patients undergoing surgical resection and pathologically confirmed curative resection or beyond criteria of curative endoscopic resection. Patients with distant metastasis or pathologically non-curative resection after surgical treatment. Patients who did not know the cancer surveillance interval were not included (
Age, sex, first degree familial history of stomach cancer, clinically important weight loss, and initial hemoglobin (<10 g/dL) were adjusted in this multivariate analysis. Patients who could not remember the cancer surveillance interval were not included ( CI, confidence interval.